Insmed Inc (NASDAQ: INSM)’s stock price has soared by 2.29 in relation to previous closing price of 79.31. Nevertheless, the company has seen a gain of 3.85% in its stock price over the last five trading days. zacks.com reported 2025-02-17 that Let’s look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
Is It Worth Investing in Insmed Inc (NASDAQ: INSM) Right Now?
The 36-month beta value for INSM is at 1.29. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INSM is 174.41M, and currently, shorts hold a 8.34% of that float. The average trading volume for INSM on February 18, 2025 was 1.81M shares.
INSM’s Market Performance
The stock of Insmed Inc (INSM) has seen a 3.85% increase in the past week, with a 11.52% rise in the past month, and a 14.92% gain in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are at 3.55% for INSM. The simple moving average for the past 20 days is 2.94% for INSM’s stock, with a 19.93% simple moving average for the past 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Truist repeating the rating for INSM by listing it as a “Buy.” The predicted price for INSM in the upcoming period, according to Truist is $48 based on the research report published on April 23, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see INSM reach a price target of $42. The rating they have provided for INSM stocks is “Outperform” according to the report published on February 15th, 2024.
Wells Fargo gave a rating of “Overweight” to INSM, setting the target price at $55 in the report published on December 08th of the previous year.
INSM Trading at 9.69% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.11% of loss for the given period.
Volatility was left at 3.55%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares surge +11.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.38% upper at present.
During the last 5 trading sessions, INSM rose by +3.26%, which changed the moving average for the period of 200-days by +226.33% in comparison to the 20-day moving average, which settled at $78.79. In addition, Insmed Inc saw 17.51% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Bonstein Sara, who sale 13,302 shares at the price of $80.00 back on Feb 11 ’25. After this action, Bonstein Sara now owns 142,204 shares of Insmed Inc, valued at $1,064,160 using the latest closing price.
Bonstein Sara, the Chief Financial Officer of Insmed Inc, sale 5,019 shares at $80.00 during a trade that took place back on Feb 12 ’25, which means that Bonstein Sara is holding 137,185 shares at $401,520 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.14 for the present operating margin
- 0.77 for the gross margin
The net margin for Insmed Inc stands at -2.52. The total capital return value is set at -0.41. Equity return is now at value -890.75, with -51.17 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.62. The debt to equity ratio resting at 2.07. The interest coverage ratio of the stock is -9.15.
Currently, EBITDA for the company is -660.18 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 43.76. The receivables turnover for the company is 8.1for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.37.
Conclusion
In conclusion, Insmed Inc (INSM) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
